A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUNAB (MPDL3280A, ANTI*PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + PACLITAXEL WITH OR WITHOUT BEVACIZUMAB COMPARED WITH CARBOPLATIN + PACLITAXEL + BEVACIZUMAB IN CHEMOTHERAPY-NAiVE
PATIENTS WITH STAGE IV NON-SQUAMOUS NON*SMALL CELL LUNG CANCER.

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2019
This article has no abstract
Epistemonikos ID: 8a85a36c5754eb592ee26e455184d88301b3ed0b
First added on: Apr 11, 2025